A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
Boehringer Ingelheim
Boehringer Ingelheim
Seagen Inc.
University of California, Davis
Fox Chase Cancer Center
Emory University
Seagen Inc.
Bayer
Tizona Therapeutics, Inc
Genentech, Inc.
Ohio State University Comprehensive Cancer Center
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
Royal Marsden NHS Foundation Trust
VLP Therapeutics
H. Lee Moffitt Cancer Center and Research Institute
Novartis
Memorial Sloan Kettering Cancer Center
Nanobiotix
Tempest Therapeutics
Asher Biotherapeutics, Inc.
Epkin
Bicara Therapeutics
Xencor, Inc.
Compugen Ltd
Thomas Jefferson University
Akamis Bio
The Methodist Hospital Research Institute
Turnstone Biologics, Corp.
Sotio Biotech Inc.
National Cancer Institute (NCI)
Astellas Pharma Inc
Astellas Pharma Inc
Inhibrx Biosciences, Inc
NGM Biopharmaceuticals, Inc
Bayer
NGM Biopharmaceuticals, Inc
University of California, San Francisco
R-Pharm
Washington University School of Medicine
Atreca, Inc.
Corvus Pharmaceuticals, Inc.
Rutgers, The State University of New Jersey
Cantargia AB
Oncorus, Inc.
Providence Health & Services
Seagen Inc.
Xencor, Inc.
National Cancer Institute (NCI)
Mendus
Amgen